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Background: PAK1 is phosphorylated and 
activated by the protein kinase CK2 in response to 
EGF. 
Results: Upon EGF stimulation, CKIP-1 recruits 
CK2 to PAK1 in membrane ruffles in a PI3K-
dependent manner. 
Conclusion: PI3K activates PAK1 at the plasma 
membrane by promoting CK2 phosphorylation of 
PAK1 via CKIP-1. 
Significance: This is the first evidence of spatial 
regulation of PAK1 activity. 
       
ABSTRACT 
      Upon growth factor stimulation, PAK1 is 
recruited to the plasma membrane and 
activated by a mechanism that requires its 
phosphorylation at S223 by the protein kinase 
CK2.  However, the upstream signaling 
molecules that regulate this phosphorylation 
event are not clearly defined. Here, we 
demonstrate a major role of the CK2α-
interacting protein CKIP-1 in activation of 
PAK1. CK2α, CKIP-1 and PAK1 are 
translocated to membrane ruffles in response to 
the epidermal growth factor (EGF), where 
CKIP-1 mediates the interaction between 
CK2α and PAK1 in a PI3K-dependent manner. 
Consistently, we observe that PAK1 mediates 
phosphorylation and modulation of the activity 
of p41-Arc, one of its plasma membrane 
substrate, in a fashion that requires PI3K and 
CKIP-1. Moreover, CKIP-1 knockdown or 
PI3K inhibition suppresses PAK1-mediated cell 
migration and invasion, demonstrating the 
physiological significance of the PI3K-CKIP-1-
CK2α-PAK1 signaling pathway. Taken 
together, these findings identify a novel 
mechanism for the activation of PAK1 at the 
plasma membrane, which is critical for cell 
migration and invasion.     
________________________________________ 
 
      PAK1, a major downstream effector of the 
Rho-family GTPases Cdc42 and Rac1, plays a 
critical role in the regulation of cell morphology 
and motility (1). In its inactive state, PAK1 forms 
a trans-inhibited dimer, where the N-terminal 
autoinhibitory domain (AID) on one PAK1 
molecule binds to and blocks the C-terminal 
catalytic domain of its counterpart (2,3).  This 
autoinhibition is relieved through binding of 
GTPases to the PBD (p21-binding domain)/CRIB 
(Cdc42/Rac-interacting) domain that partially 
overlaps with AID, leading to autophosphorylation 
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at specific sites, including Thr-423 within the 
activation loop, and consequent activation of 
PAK1 (4).  PAK1 is recruited to the plasma 
membrane via the SH3-containing proteins Nck 
and Grb2 upon stimulation by growth factors (5-
9), leading to efficient activation of PAK1.  
      CK2 (Casein Kinase 2) is a serine/threonine 
kinase that regulates a broad range of biological 
processes, including cell growth and survival, gene 
expression, and actin cytoskeleton organization 
(10,11). CK2 is a tetramer composed of two α 
catalytic subunits and two β regulatory subunits, 
but the precise mechanism of its regulation is not 
fully understood.  Emerging evidence shows that, 
in cancer cells, CK2 is frequently elevated and 
translocated into the nucleus  to regulate gene 
expression (12,13) and  also targeted to the plasma 
membrane to regulate actin cytoskeleton 
organization by acting on proteins such as WASP 
(14), CRN2 (15), myosin-9 (16) and WAVE2 (17). 
Therefore, the regulated translocation of CK2 to 
different cellular compartments may be critical for 
its functional regulation (11).   
      The Pleckstrin homology (PH) domain-
containing protein CKIP-1, identified as a CK2α 
interacting protein (18), recruits CK2α to the 
plasma membrane (19).  Accumulating evidence 
indicates that CKIP-1 is involved in various 
cellular processes including cell proliferation, 
differentiation, morphology and migration in 
various human cell lines including human 
osteosarcoma U2-OS and macrophage (20-22). 
CKIP-1 binds to multiple proteins (e.g., CK2α, 
CPα, Akt, C-Jun ATM, IFP/Nmi and Smurf1) via 
its PH domain, implicating its role as a scaffold 
protein in various signaling pathways (23).  Of 
note, CKIP-1 appears to associate with the plasma 
membrane through binding to phosphoinositides 
and to regulate muscle differentiation in mouse 
myoblast C2C12 cells (24) as well as myoblast 
fusion in mouse and zebrafish, in PI3K-dependent 
fashion (25). These observations have raised the 
possibility that CKIP-1 may serve as a key 
controller of cellular processes regulated by PI3K. 
      We have recently demonstrated that CK2 
catalyzes phosphorylation of PAK1 at S223, 
which is critical for the activation of the kinase  
(26).  Here, we show evidence that CKIP-1 
appears to recruit CK2α to PAK1 in response to 
EGF in a PI3K-dependent manner. Consequently, 
inhibition of either CKIP-1 or PI3K activity blocks 
PAK1-mediated actin cytoskeleton dynamics and 
cell migration.  These results demonstrate the role 
of CKIP-1 in EGF-induced activation of PAK1, 
providing a novel regulatory mechanism for PAK1 
signaling.   
 
EXPERIMENTAL PROCEDURES 
      Cell cultures—The human prostate cancer PC3 
cells were maintained in RPMI 1640 containing 
10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin in a humidified incubator 
(37°C and 5% CO2). The benign prostate epithelial 
RWPE-1 cells were cultured in keratinocyte 
serum-free medium (K-SFM) containing 5 ng/ml 
of epidermal growth factor (EGF) and 50 µg/ml of 
bovine pituitary extract (BPE). CKIP-1 
knockdown PC3 and RWPE-1 cells were grown in 
suitable medium containing 2 µg/ml of puromycin.  
      Lentiviral infection—Standard lentiviral 
transduction was performed as described 
previously (27). In brief, lentiviral transduction 
was used for CKIP-1 knockdown and GFP-
PAK1WT overexpression in prostate cancer cells 
(PC3 and RWPE-1). Lentiviral short hairpin 
RNAs (shRNAs) specific for CKIP-1 were 
purchased from Sigma-Aldrich (sh1, TRCN00001 
-65913; sh2, TRCN0000165914). For viral 
production, 293T cells were cotransfected with 
pLKO.1-shNT or pLKO.1-CKIP-1 specific 
shRNAs, and packaging and envelope vectors 
psPAX2 and pCMV-VSV-G using the 
LipofectamineTM LTX transfection reagent 
(Invitrogen). Transfection was performed as 
described previously (27). 
      Western blot analysis—Whole cell extracts 
were prepared in RIPA buffer (50 mM Tris pH 





















deoxycholate, 0.1% SDS) with protease inhibitors 
(28). For immunoprecipitation, cells were lysed 
lysed in IP lysis buffer (25 mM HEPES pH7.4, 
150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100) 
and mixed with protein G-Sepharose beads (GE 
healthcare) prebound to mouse normal IgG and 
anti-GFP (Santa Cruz) for 4 h with rotation at 4°C. 
Pull-down beads were washed four times with IP 
wash buffer (25 mM HEPES pH7.4, 1 M NaCl, 1 
mM EDTA, 0.5% Triton X-100). Plasma 
membrane fractions were prepared using Mem-
PERTM Eukaryotic Membrane Protein Extraction 
Reagent Kit (Thermo Scientific) following the 
manufacture`s protocols. Protein concentration 
was quantified using Bradford to calculate the 
ratio of each sample volume. The protein samples 
were resolved on a 10% SDS–PAGE gel and 
transferred to a nitrocellulose membrane. 
Antibodies used in this study include anti-
phospho-PAK1S223 (26), anti-phospho-PAK1S144, 
anti-PAK1, anti-Na/K-ATPase (Cell Signaling), 
anti-CK2α, anti-GFP (Santa Cruz), anti-α-Tubulin 
(Neo Markers), anti-phospho-p41-ArcT21 (ECM 
Biosciences) and anti-CKIP-1 (Sigma-Aldrich) 
antibodies. 
      Immunofluorescence staining—Cells were 
grown on glass coverslips and transfected with 
either control (NT) or CKIP-1 specific shRNA 
constructs.  After 24 h, cells were washed twice in 
cold PBS before fixation with 4% PFA for 10 min 
at room temperature (RT).  After fixation, the cells 
were washed three times with PBS for 5 min each 
and incubated with the blocking buffer containing 
5% BSA and 5% normal goat serum. Coverslips 
were incubated with primary antibodies overnight 
at 4°C or with Rhodamine-labeled Phalloidin in 
PBS for 30 min at room temperature. After 
washing three times with PBS, cells were treated 
with secondary antibodies for 1 h.  DNA was 
stained with 0.1 ug/ml DAPI (4', 6-diamidino-2-
phenylindole) in PBS for 1 min. Cells were 
mounted in a mounting medium (KPL) and 
imaged on an Olympus IX71 inverted microscope 
(Olympus Imaging America Inc). 
      Cell migration and invasion assays—For the 
wound-healing migration assay, PC3 cells were 
seeded at 70% confluence into 6-well culture 
dishes and, 24 h later, infected with CKIP-1-
specific or control shRNA lentivirus. When the 
cells grew to confluence, scratch wounds were 
made on the monolayers using sterile 200 µl 
pipette tips. After 24 h incubation, the wounded 
monolayers were washed gently twice with 1X 
PBS to remove the detached cells and replenished 
with fresh media. The cells were fixed with 4% 
paraformaldehye for 30 minutes and then 
photographed. Wound areas were measured using 
ImageJ software.  Cell invasion assay was 
performed using the cell invasion kit (Transwell 
Boyden’s chamber with TranswellTM Permeable 
Support Inserts Coated with Cultrex® BME 
(basement membrane extract, Corning Costar) 
according to the manufacture’s instruction. 
Briefly, serum-starved PC3 and RWPE-1 (2 × 105 
cells/well) cells were added to the upper chamber, 
whereas suitable media containing 10% FBS was 
added to the lower chamber and cultured in an 
incubator for 24 h. Nonmigrating cells were gently 
removed from the upper surface of the filter with a 
cotton swab; migrating cells which were attached 
to the lower surface of the filter were fixed and 
stained with hematoxylin for counting. 
      Soft agar colony forming assay—Anchorage-
independent growth was determined by examining 
cell growth in soft agar. RWPE-1 cells (3 × 104) 
were seeded in 0.3% agar on top of a base layer of 
0.6% agar containing K-SFM (keratinocyte serum-
free medium) and 1 μg/ml of puromycin. The cells 
were placed in a 37°C, 5% CO2 incubator. After 2 
weeks, colonies were stained with crystal violet 
(0.05%) and counted. Colonies were counted 
under a microscope (Nikon Eclipse Ti; Melville, 




      PAK1, CK2α and CKIP-1 are recruited to 





















regulates cell polarity and migration in response to 
growth factors by modulating the actin 
cytoskeleton (29-31).  Immunofluorescence 
microscopy indicates that EGF induces the 
formation of membrane ruffles at the leading edge 
of polarized PC3 prostate cancer cells (Fig. 1A, F-
actin) by promoting the recruitment of PAK1, 
CK2α, and CKIP-1 to membrane ruffles (Fig. 1A).  
Increased PAK1 activity is associated with auto-
phosphorylation of specific sites including S144 
(32).  Activated PAK1 phosphorylates T21 of p41-
Arc, a subunit of the human Arp2/3 complex, at 
the plasma membrane (33).  Thus, PAK1 activity 
can be assessed by the phosphorylation state of 
S144 of PAK1 (PAK1S144) and T21 of p41-Arc 
(p41-ArcT21).  EGF treatment does not affect the 
expression of CK2α, CKIP-1, or PAK1, but does 
increase phosphorylation of PAK1S144 and p41-
ArcT21 (Fig. 1B).  Given that CKIP-1 interacts with 
CK2α (19), we addressed the role of CKIP-1 in 
CK2 activation of PAK1. CKIP-1 does not 
regulate the expression of CK2α or PAK1 (Fig. 
1C); instead, it mediates the EGF-induced 
recruitment of CK2α to membrane ruffles (Fig. 
1D).  It is of note, however, that PAK1 
localization to the plasma membrane is not 
regulated by CKIP-1 (Fig. 1D).  Thus, CKIP-1 
seems to play a key role in EGF-induced PAK1 
activation by recruiting CK2α to the plasma 
membrane. 
 
      CKIP-1 mediates EGF-induced PAK1 
interaction with CK2α—To gain more insights 
into the role of CKIP-1 in EGF-induced PAK1 
activation, we assessed the effect of CKIP-1 
knockdown on the interaction between CK2α and 
PAK1.  Upon EGF treatment in PC3 cells, PAK1 
and CK2α are colocalized and interact with each 
other at the plasma membrane (Figs. 2A and 2C).  
However, this interaction is greatly reduced by 
CKIP-1 knockdown (ShCKIP-1 in Figs. 2A and 
2C).  This is perhaps because CKIP-1 silencing 
results in decreased localization of CK2α to the 
plasma membrane (Fig. 2B), which renders PAK1 
inactive (PAK1S144) and unable to phosphorylate 
its substrate p41-Arc at T21 (p41-ArcT21) (Fig. 
2D).   Consequently, CKIP-1 silencing decreases 
the colocalization of CK2α with an active form of 
PAK1 (phospho-PAK1S144) (Fig. 2E) and that of 
F-actin with either phospho-PAK1S144 (Fig. 2F) or 
phospho-p41-ArcT21 (Fig. 2G) to the cell 
periphery. Collectively, these results indicate that 
CKIP-1 functions to promote CK2-dependent 
phosphorylation and activation of PAK1 by 
recruiting CK2α to PAK1 to the plasma 
membrane.    
 
      Expression of a constitutively active PAK1 
(PAK1S233E) bypasses the requirement for CKIP-1 
in PAK1-induced cell polarity and migration—
Our recent work shows that CK2 phosphorylates 
S223 of PAK1, and that a phosphomimetic 
mutation at S223 (S to E) generates a 
constitutively active PAK1 (26).  We find that, 
upon EGF treatment, PAK1 is recruited to the 
plasma membrane (Fig. 1A) and phosphorylated at 
S223 (Figs. 3A and 3B). To understand further 
CKIP-1 regulation of PAK1, we infected CKIP-1 
knockdown PC3 cells with a lentivirus expressing 
GFP-PAK1 and examined the activity and 
localization of PAK1 using anti-phospho-specific 
PAK1 (S223) antibody. Western blot analysis 
shows that CKIP-1 silencing decreases S223 
phosphorylation of PAK1 (Fig. 3C).  In addition, 
fluorescence microscopy analysis shows that 
CKIP-1 knockdown results in decreased 
phosphorylation at S223 (Fig. 3D, middle) and, 
consequently, in loss of cell polarity (Fig. 3D, 
CKIP-1), and that the polarization defect of CKIP-
1 knockdown cells (Fig. 2, shCKIP-1) is partially 
rescued by overexpression of GFP-PAK1 (Fig. 3E, 
shCKIP-1). 
      To examine the physiological significance of 
CKIP-1 regulation of PAK1 activity, we 
investigated whether PAK1-induced cell migration 
and invasion are affected by CKIP-1 knockdown.        
Wound healing assays show that CKIP-1 silencing 





















type GFP-PAK1 by 70%, but this inhibitory effect 
is not observed in PC3 cells expressing GFP-
PAK1S223E (Fig. 3F).  Similarly, cell invasion 
assays using Transwell Boyden’s chamber system 
indicate that invasion of PC3 cells expressing 
GFP-PAK1 is inhibited 70 – 80% by CKIP-1 
knockdown, and that, however, CKIP-1 inhibition 
does not significantly reduce the invasiveness of 
PC3 cells expressing GFP-PAK1S223E (Fig. 3G). 
These results indicate that CKIP-1 knockdown 
suppresses PAK1-mediated cell migration and 
invasion. 
 
    The CKIP-1-mediated interaction between 
CK2α and PAK1 is regulated by PI3K—CKIP-1, 
as a Pleckstrin Homology domain-containing 
protein, is recruited by phosphatidylinositol 3‐
phosphate (PI3P) to the plasma membrane in a 
PI3K (phosphatidylinositol 3‐kinase)-dependent 
manner (24).  This notion is further supported by 
the finding that the inhibition of PI3K signaling 
reduces plasma membrane localization of CKIP-1 
(34). An early study showed that PAK1 regulates 
the invasiveness of breast cancer cells via PI3K 
signaling (35). These observations suggest that 
PI3K regulates PAK1 activity through CKIP-1.  
To address this idea, we treated PC3 cells with the 
PI3K inhibitors LY294002 and wortmannin and 
examined the subcellular localization of CKIP-1, 
CK2α and PAK1.  Both LY294002 and 
wortmannin inhibit the EGF-induced membrane 
localization of CKIP-1 (Fig. 4A), CK2α and PAK1 
(Figs. 4D and 4E), and this may be associated with 
a decrease in the formation of membrane ruffles 
(Figs. 4A, 4D and 4E). In agreement, Western blot 
analysis demonstrates low levels of CKIP-1 and 
CK2α at the plasma membrane (Fig. 4B) and 
decreased PAK1 activity, as measured by the 
phosphorylation of PAK1S144 and p41-ArcT21 (Fig. 
4C), in PC3 cells treated with LY294002 or 
wortmannin.   
      Consistently, the PI3K inhibitors LY294002 
(Fig. 5) and wortmannin (data not shown) disrupt 
the interaction of PAK1 with CK2α and CKIP-1 
(Fig. 5A) and inhibit the colocalization of CKIP-1 
with either CK2α (Fig. 5B) or PAK1 (Fig. 5C) and 
that of PAK1 with CK2α (Fig. 5D).  Thus, PI3K 
may regulate the CKIP-1-mediated interaction 
between CK2α and PAK1 by controlling the 
plasma membrane localization of CKIP-1. 
 
      Expression of a constitutively active PAK1 
(PAK1S233E) bypasses the requirement for PI3K in 
the EGF-induced activation of PAK1—Given that 
PI3K acts as an activator of PAK1 (Fig. 4 and 5), 
we examined the effects of PI3K inhibition on the 
CK2-mediated phosphorylation and activation of 
PAK1.  Akt is phosphorylated at S473 by PI3K, 
thus this phosphorylation is used as a biochemical 
marker for PI3K activation (36).  Our results show 
that LY294002 inhibits the phosphorylation of 
AktS473, PAK1S223 and p41-ArcT21 (Fig. 6A) and the 
EGF-induced colocalization of phospho-PAK1S223 
and phospho-p41-ArcT21 to the membrane ruffles 
(Fig. 6B).  However, expression of the 
constitutively active PAK1 (PAK1S223E) induces 
the phosphorylation of p41-ArcT21 (Fig. 6C) and 
PAKS144 (Fig. 6D) even in LY294002-treated PC3 
cells.  Furthermore, the migration defect of these 
cells is rescued by the expression of GFP-
PAK1S223E (Fig. 6E).  Thus, these observations 
indicate that PI3K is required for PAK1-mediated 
cell migration. 
 
      CKIP-1 is required for PAK1-mediated 
malignant transformation of the benign prostate 
RWPE-1 cells— Overexpression of PAK1 induces 
malignant transformation of the benign prostate 
RWPE-1 cells in vitro and in vivo (26).  Given that 
CKIP-1 regulates PAK1 activity (Figs. 2 and 3), 
we examined the effects of CKIP-1 silencing on 
the PAK1-mediated migration and invasion of 
RWPE-1 cells.  Overexpression of PAK1 induces 
the formation of membrane ruffles, which, 
however, is inhibited by CKIP-1 knockdown (Fig. 
7A). As observed in PC3 cells (Fig. 3), CKIP-1 
knockdown decreases phosphorylation of PAK1 





















(Fig. 7C) and proliferation (Fig. 7D) of RWPE-1 
cells. These results suggest that CKIP-1 regulates 
prostate cancer migration and proliferation by 




      PAK1 is a pluripotent kinase that regulates 
numerous cellular processes, including cell growth 
and proliferation, actin cytoskeleton organization, 
cell cycle and apoptosis (37-40).  It remains 
unknown, however, how PAK1 can perform such 
diverse functions remains unknown. It has been 
suggested that the fine control of localization and 
activation of PAK1 may be the mechanism used 
by the cell to activate the right PAK1-dependent 
pathway according to the cell cycle status or in 
response to extracellular stimuli (39).  An early 
study showed that PI3K activation induces PAK1 
kinase activity in a Cdc42/Rac1 or an Akt-
independent mechanism (41). However, the 
underlying mechanism remains unknown. In this 
study, we establish the role of CKIP-1 in the PI3K 
activation of PAK1 in response to EGF.  CKIP-1 
was originally identified as a CK2α-interacting 
protein.  However, it has not been demonstrated 
whether CKIP-1 is involved in phosphorylation of 
CK2 substrates (18,19,23).  Our data show for the 
first time that CKIP-1 delivers CK2α to PAK1 in 
response to EGF, and that this process is regulated 
by PI3K, demonstrating a mechanistic link 
between CK2 and PI3K signaling. 
      Emerging evidence indicates that PI3K 
mediates plasma membrane association of CKIP-1 
(23).  CKIP-1 exhibits a very broad spectrum of 
binding to phosphoinositols through its PH domain 
(19).  In myoblast C2C12 cells, CKIP-1 binds to 
PI3P (phosphoinositol-3-phosphate) at the plasma 
membrane in response to insulin and regulates 
muscle differentiation; however, PI3K inhibition 
or coexpression of PI3K (∆p85), a dominant 
negative mutant of PI3K, leads to nuclear 
accumulation of CKIP-1 (24).  CKIP-1 bound to 
phosphoinositides via its PH domain regulates cell 
morphology and lamellipodia formation by 
recruiting the Arp2/3 complex to the plasma 
membrane (25).  Subcellular localization of CKIP-
1 is dependent on the cell type.  CKIP-1 localizes 
in the nucleus in osteosarcoma Saos-2, mouse 
preosteoblastic MC-3T3 and rodent fibroblast Rat-
1 cells, but is also found at the plasma membrane 
in monkey kidney COS-7 cells (18).  Therefore, it 
has been suggested that CKIP-1, as a scaffolding 
protein, may shuttle between the nucleus and the 
plasma membrane and redistributes signaling 
complexes between these two compartments in a 
PI3K-dependent manner (24).   
      An intriguing finding in the present study may 
be that PI3K tightly controls PAK1 activity by 
regulating EGF-induced localization of CK2α and 
PAK1 to the plasma membrane. We show that 
CKIP-1, CK2α and PAK1 are recruited to the 
leading edge of the cells in response to EGF (Fig. 
1), and that this process is regulated by PI3K (Fig. 
4).  Accordingly, PAK1 phosphorylation of one of 
its plasma membrane substrates p41-ArcT21 occurs 
in PI3K-, CKIP-1- and CK2α−dependent manners. 
These findings reveal a novel signaling pathway 
by which PI3K activates PAK1 in response to 
EGF (PI3K CKIP-1CK2 PAK1). Our data 
provide evidence that PI3K regulates localization 
of PAK1 to the membrane ruffles (Figs. 4D and 
4E), but the underlying mechanism is unknown. 
PAK1, like CKIP-1, associates with the plasma 
membrane through phosphoinositides (42), and 
this process may be regulated by Nck and Grb2 
(8,9).  PI3K/Akt also appears to regulate plasma 
membrane localization of PAK1; a mutation of the 
Akt phosphorylation site in PAK1 blocks PAK1 
activation and inhibits PAK1 redistribution in 
response to chemoattractant stimulation, but 
LY294002 treatment results in a rapid loss of cell 
polarity and PAK1 redistribution (43). Thus, these 
observations are consistent with our results that 
PI3K regulates localization of PAK1 to the plasma 
membrane. 
        PAK1 acts as a convergence point of many 





















dysregulated in human cancers and thus is 
activated by various signaling factors, including 
p21 GTPases, thrombin, growth factors and 
hormones (38,40).  Phosphorylation of PAK1 at 
T423 in the kinase activation loop is crucial for 
enzymatic activity. Binding of GTPases and lipids, 
such as sphingosines, to PAK1 results in exposure 
of the activation loop of the kinase domain (44), 
making it accessible for T423 phosphorylation by 
3-phosphoinositide-dependent kinase 1 (PDK1) 
(45). It should be noted that PDK1 
phosphorylation of PAK1 is not blocked by 
pretreatment with PI3K inhibitor wortmannin or 
when PDK1 was mutated to prevent 
phosphatidylinositol binding, indicating that this 
process is independent of PI3K activity (46). 
Therefore, T423 phosphorylation by PDK1 may 
be necessary but not sufficient for the activation of 
PAK1.  Our results have demonstrated that CK2 
phosphorylation of S223 is crucial for activation 
of PAK1 (26), and that this process is regulated by 
PI3K (this study).  The kinase activity of a 
constitutively active PAK1 (PAK1H83,86L), 
postulated to mimic GTPase-induced structural 
changes (47), requires phosphorylation of S223, 
suggesting that S223 may become available for 
phosphorylation by CK2 after the conformational 
change (26). Therefore, PI3K-dependent, CKIP-1-
mediated recruitment of CK2α to the plasma 
membrane is essentially required for the activation 
of PAK1. 
      PAK1 is the major isoform of PAKs expressed 
in most cancers (38,48) and its expression is 
sufficient to promote prostate tumor growth (49).  
Given that S223 of PAK1 is not conserved in other 
PAK family members, CK2-mediated S223 
phosphorylation is considered a unique regulatory 
mechanism for PAK1 activation (26). Activation 
of oncogenic kinases by elevated expression is a 
common feature of human primary tumors.  
However, there is no significant difference in 
PAK1 expression between prostate normal and 
malignant tissues (GeneCards, www.genecards. 
org). Instead, blocking S223 phosphorylation leads 
to growth inhibition of prostate cancer PC3 cells 
(26).  Therefore, PI3K-, CKIP-1-, and CK2-
dependent phosphorylation of PAK1 plays a key 
role in malignant transformation of prostate cells. 
This concept is also supported by the observation 
that the silencing of CKIP-1 by shRNA inhibits 
PAK1-mediated migration and invasion of benign 
prostate epithelial RWPE-1 cells (Fig. 7). Aberrant 
activation of growth factor receptor signaling is 
associated with human cancer (38), and the EGF 
receptor is overexpressed in PC3 cells (50). These 
observations strengthen the view that CKIP-1-
mediated CK2 phosphorylation of PAK1, which is 
triggered by PI3K activation, may be the principal 
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FIGURE 1. PAK1, CK2α and CKIP-1 are recruited to membrane ruffles in response to EGF.  PC3 
cells were serum-starved for 24 h and then incubated in the absence (-) or the presence (+) of EGF (100 
ng/ml) for 1 h.  A, Fluorescence microscopy images of PC3 cells stained with rhodamine-labeled 
phalloidin (red) or an antibody to PAK1, CK2α or CKIP-1 (green) (top) and quantification of plasma 
membrane (PM) localization of PAK1, CK2α and CKIP-1 (bottom).  B, Whole-cell lysates of PC3 cells 





















with (Sh) or without (NT) CKIP-1 knockdown were analyzed by Western blotting using anti-CK2α or 
anti-PAK1 antibody. D, Fluorescence microscopy images of CKIP-1 knockdown PC3 cells stained with 
anti-CK2α or anti-PAK1 antibody (left) and quantification of PM localization of PAK1 and CK2α  
(right).  The quantitative evaluation of the immuno-staining patterns was performed on at least 1000 cells 
per sample, in at least three independent experiments, and the results were expressed as the percentages of 
cells with PM localization of the respective proteins (A and D).  ***P <0.001.  
 
FIGURE 2. CKIP-1 recruits CK2α to PAK1 to membrane ruffles in response to EGF.  PC3 cells 
with (Sh) or without (NT) CKIP-1 knockdown were serum-starved for 24 h and then treated with EGF 
(100 ng/ml) for 1 h.  A, PC3 cells were costained with anti-CK2α (green) and anti-PAK1 (red) antibodies.  
B, The plasma membrane-enriched fraction of PC3 cells was analyzed by Western blotting using 
antibodies to CKIP-1, CK2α or PAK1. The plasma membrane Na+/K+-ATPase was used as a loading 
control.  C, GFP-PAK1 expressed in PC3 cells (a ShNT and two Sh-CKIP-1s) was immunoprecipitated 
using anti-GFP antibody (IP), and blots were probed with antibodies to the indicated proteins.  D, Whole-
cell lysates of PC3 cells with (Sh) or without (NT) CKIP-1 knockdown were blotted with antibodies to 
the indicated proteins.  E, Colocalization of CK2α (green) with an activated form of PAK1, PAK1S144 
(pS144, red) in PC3 cells.  F and G, PC3 cells were costained with rhodamine-labeled phalloidin (red) 
and either anti-phospho-PAK1S144 antibody (green) (F) or anti-phospho-p41-ArcT21 antibody (green) (G).  
DNA was stained with DAPI (blue) in A, E, F and G. 
 
FIGURE 3.  Expression of a constitutively active PAK1 (PAK1S233E) bypasses the requirement for 
CKIP-1 in EGF-induced cell polarity and migration.  PC3 cells were serum-starved for 24 h and then 
stimulated by EGF (100 ng/ml) for 1 h. A, PC3 cells were stained with anti-phospho-PAK1S144 antibody 
(red).  B, Quantification of cells stained with anti-phospho-PAK1S223 antibody. Cells with plasma 
membrane (PM) localization of phospho-PAK1S144 were quantified as described above (Fig. 1). ***P 
<0.001.  C, Western blot analysis of S223 phosphorylation of PAK1. Whole cell lysates of CKIP-1 
knockdown (CKIP-1) and control (NT) PC3 cells expressing GFP-PAK1 were blotted with antibodies to 
the indicated proteins. D, PC3 cells stimulated by EGF were stained with anti-phospho-PAK1S223 
antibody (green) and rhodamine-labeled phalloidin (red). E, Immunofluorescence analysis of the 
localization of GFP-PAK1 and phospho-PAK1S223.  PC3 cells expressing GFP-PAK1 were stained with 
anti-phospho-PAK1S223 antibody (middle).  DNA was stained with DAPI (blue) in D and E.  F, Wound 
healing assay of PC3 cells expressing GFP-PAK1 or GFP-PAK1S223E (left). The results were expressed as 
the percentages of the remaining area as determined by normalizing the area of wound after 24 h (black 
bars) to the initial wound area at 0 h (white bars, set to 100%) (left).  Each bar represents the mean ± s.e 
of five fields counted (***, P<0.001) (right). G. Invasion assay of PC3 cells expressing GFP-PAK1Wt or 
GFP-PAK1S223E.  Cell invasiveness was assessed using a Transwell Boyden chamber assay (top). The 
invasion rate was determined by counting the number of cells having migrated through the membrane into 
the lower chamber, and the results were expressed as a percentage relative to control cells (shNT cells 
expressing GFP-PAK1, set to 100%).  Each bar represents the mean ± s.e of five fields counted (***, 
P<0.001) (bottom). 
 
FIGURE 4. PI3K regulates the localization of CKIP-1 to the plasma membrane. PC3 cells were 
serum-starved 24 h, stimulated by EGF (100 ng/ml) for 1 h, and then treated with LY294002 (25 µM) for 





















anti-CKIP-1 antibody (top) and quantification of plasma membrane (PM) localization of CKIP-1 as 
described in Fig. 1 (bottom). B, The plasma membrane-enriched fraction of PC3 cells was analyzed by 
Western blotting using antibodies to CKIP-1, CK2α and PAK1. Na+/K+-ATPase was used as loading 
control.  D, PAK1 activity in PC3 cells treated with (+) or without (-) LY294002 or wortmannin. C. 
Western blot analysis of the phosphorylation of PAK1S144 and p41-ArcT21. Whole-cell lysates were blotted 
with antibodies to the indicated proteins. D and E, PC3 cells were costained with rhodamine-labeled 
Phalloidin (red) and either anti-CKIP-1, CK2α or PAK1 antibody (green). DNA was stained with DAPI in 
D and E.     
 
FIGURE 5.  PI3K regulates the interaction of PAK1 with CK2α and CKIP-1.  PC3 cells were 
incubated and treated with EGF and LY294002 as described above (Fig. 4). A, Western blot analysis of 
the interaction of PAK1 with CK2α and CKIP-1. GFP-PAK1 expressed in PC3 cells (- LY and + LY) 
was immunoprecipitated using anti-GFP antibody (IP) and blotted with anti-GFP, anti-CK2α or anti-
CKIP-1 antibody (IB).  B, PC3 cells were costained with anti-CKIP-1 (green) and anti-CK2α (red) 
antibodies.  C and D, PC3 cells were costained with anti-PAK1 antibody (red) and either anti-CKIP-1 
antibody (green) (C) or anti-CK2α antibody (green) (D). DNA was stained with DAPI in B, C and D. 
 
FIGURE 6. Expression of a constitutively active PAK1 (PAK1S233E) bypasses the requirement for 
PI3K in EGF-induced PAK1 activation. PC3 cells were incubated and treated with EGF and LY294002 
as described above (Fig. 4). A, Whole-cell lysates of PC3 cells were blotted with antibodies to the 
indicated proteins. AKT phosphorylation at S473 (AKTS473) was used as an indicator of PI3K activation.  
B, Colocalization of phospho-PAK1S223 and phospho-p41-ArcT21 in PC3 cells.  C, PC3 cells expressing 
GFP-PAK1 or GFP-PAK1S223E were costained with anti-phospho-p41-ArcT21 and anti-phospho-
PAK1S223antibodies.  D, Whole-cell lysates of PC3 cells expressing GFP-PAK1 or GFP-PAK1S223E were 
blotted with antibodies against the indicated proteins.  E, Wound healing assay of PC3 cells expressing 
PAK1 or GFP-PAK1S223E. The results were expressed as the percentages of the remaining area as 
determined by normalizing the area of wound after 24 h (black bars) to the initial wound area at 0 h 
(white bars, set to 100%) (left).  Each bar represents the mean ± s.e of five fields counted (***, P<0.001) 
(right).  DNA was stained with DAPI in B and C. 
 
FIGURE 7. CKIP-1 is required for PAK1-mediated malignant transformation of the benign 
prostate RWPE-1 cells.  A, RWPE-1 cells (shNT and shCKIP-1) expressing GFP-PAK1 were incubated 
in serum-containing medium and stained with rhodamine-labeled phalloidin. DNA was stained with 
DAPI (blue). B, Whole-cell lysates of RWPE-1 cells expressing GFP-PAK1 were blotted with antibodies 
to the indicated proteins. C, Invasion assay of RWPE-1 cells expressing GFP-PAK1.  Cell invasiveness 
was assessed using a Transwell Boyden chamber assay (top), and the invasion rate was determined as 
described in Fig. 3G (bottom).  D, Anchorage-independent growth assay of RWPE-1 cells (shNT and 
shCKIP-1) expressing GFP-PAK1. GFP-PAK1-induced shNT or shCKIP-1 cells were visualized by 
phase-contrast microscopy (top). Quantitative analysis of colony numbers (mean ± SD) in week 3 is 
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